Back to search results

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

Abroad (travel likely)RecruitingPHASE3

Conditions

Renal Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University Of UA Cancer Center(UACC)/DH-SJHMC, Phoenix, Arizona, United States

  • University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

  • UCSF Helen Diller Family Comphrensive Cancer Center - Hemato, San Francisco, California, United States

  • Norton Cancer Institute, Norton Healthcare Pavilion, Louisville, Kentucky, United States

  • Ochsner Clinic Foundation, New Orleans, Louisiana, United States

  • GU Research Network/Urology Cancer Center, Omaha, Nebraska, United States

  • Nebraska Cancer Specialists, Omaha, Nebraska, United States

  • Northwell Health/Monter Cancer Center, Lake Success, New York, United States

  • Mainstreet Physicans Care, Rochester, New York, United States

  • Precision Cancer Research/Dayton Physicians Network - Treatment, Kettering, Ohio, United States

  • Oregon Health and Science University, Portland, Oregon, United States

  • St. Luke's Hospital, Easton, Pennsylvania, United States

  • HOPE Cancer Center of East Texas, Tyler, Texas, United States

  • Medical Oncology Associates, PS (dba Summit Cancer Centers), Spokane, Washington, United States

  • Beijing Cancer Hospital, Beijing, China

    Contact: Study coordinator (Bixia Tang, MD, PhD) · bixiatang_med@126.com · 13810211044

  • Zhongshan Hospital Affiliated to Fudan University, Shanghai, China

    Contact: Study coordinator (Xiaoyi Hu, MD, PhD) · hu.xiaoyi@zs-hospital.sh.cn · 13917166233

  • Fondazione del Piemonte per l'Oncologia_Istituto di Candiolo, IRCCS_ Oncologia Medica, Candiolo, Italy

  • A.O. Cannizzaro_UOS Oncologia Medica, Catania, Italy

  • IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) UO Oncologia Medica, Meldola (FC), Italy

  • Istituto Europeo di Oncologia_Unità Oncologia Medica Urogenitale e Cervico Facciale, Milan, Italy

  • Istituto Nazionale dei Tumori-Fondazione Pascale- SC Oncologia Medica, Naples, Italy

  • Azienda Ospedaliero-Universitaria Maggiore della Carità Novara_SC Oncologia Medica, Novara, Italy

  • Istituti Clinici Scientifici Maugeri Spa-SB_ UO Oncologia Medica, Pavia, Italy

  • Azienda Ospedaliero Universitaria Pisana_ UO Oncologia Medica Universitaria, Pisa, Italy

  • Fondazione Policlinico Universitario A. Gemelli, U.O.C. Oncologia Medica, Roma, Italy

  • Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny, Brzozów, Poland

  • Szpitale Pomorskie Sp. z o.o. Oddział Onkologii i Radioterapii, Gdynia, Poland

  • Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie Sp. z o.o. Oddział Onkologii Klinicznej z Pododdziałem Dziennym, Krakow, Poland

  • Clinical Research Center Sp. z o.o., Medic-R Sp. K., Poznan, Poland

  • National Cancer Center - Center For Prostate Cancer, Goyang-si, South Korea

  • CHA Bundang Medical Center, CHA University, Seongnam-si, South Korea

  • Severance Hospital, Yonsei University Health System - Medical Oncology, Seoul, South Korea

  • Asan Medical Center - University of Ulsan College of Medicin, Seoul, South Korea

  • Samsung Medical Center - Hematology-Oncology, Seoul, South Korea

  • H.G.U. de Elche, Elche, Spain

  • Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain

  • Hospital Universitario 12 de Octubre, Madrid, Spain

  • H.U. Virgen de la Victoria, Málaga, Spain

Study leads

  • Pamela Munster, M.D.

    Study Chair

    University of California, San Francisco

  • Rahul Aggarwal, M.D.

    Study Chair

    University of California, San Francisco

View source on ClinicalTrials.gov(opens in a new tab)